| Field | Specification |
|---|---|
| Target | |
| Alternative names | Apoptosis regulator BAX;Bcl-2-like protein 4;Bcl2-L-4;BAX;BCL2L4; |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human Bax, different from the related mouse and rat sequences by one amino acid. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes apoptosis regulator BAX in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and immunoprecipitation. The predicted molecular weight is 21.2 kDa, and the supplier reports an observed band at about 21 kDa.
BAX is a pro-apoptotic effector of the Bcl-2 family that is mostly cytosolic in healthy cells. Apoptotic signals cause BAX to insert into the mitochondrial outer membrane and oligomerize, permeabilizing it and releasing cytochrome c to activate caspases. BAX and BAK together are the gatekeepers of intrinsic apoptosis.
| Target | Apoptosis regulator BAX (gene BAX; UniProt Q07812, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 21.2 kDa |
| Observed MW | 21 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Immunoprecipitation | 0.5–2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human THP-1 cells, human MCF-7 cells, human A549 cells, human HeLa cells, rat brain tissue, rat C6 cells, mouse brain tissue, mouse Neuro-2a cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 12% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A549 cells.
Samples with a confirmed result (IP): HeLa cells.
Samples with a confirmed signal (flow cytometry): MCF-7 cells.
Immunogen
Synthetic peptide from the N-terminal region of human bax. It differs from the mouse and rat sequences at one residue.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. Tissue expression noted by UniProt (human): Expressed in a wide variety of tissues. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xu Haotian et al. (2025) o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis. Journal of Experimental & Clinical Cancer Research. 10.1186/s13046-025-03365-z
Liangliang Dai et al. (2021) TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling. Biomaterials. 10.1016/j.biomaterials.2021.121010
Zhang Nan et al. (2022) The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Experimental and Molecular Medicine. 10.1038/s12276-022-00735-x
Ze Zhang et al. (2025) Cardiotoxicity of tris(2-chloroethyl) phosphate exposure: Insights into the role of oxygen sensor mediated energy metabolism remodeling. Journal of Hazardous Materials. 10.1016/j.jhazmat.2025.137113
Sun Zhenxing et al. (2023) Ultrasound-targeted microbubble destruction promotes PDGF-primed bone mesenchymal stem cell transplantation for myocardial protection in acute Myocardial Infarction in rats. Journal of Nanobiotechnology. 10.1186/s12951-023-02204-7
Ze Zhang et al. (2022) Oxygen sensors mediated HIF-1α accumulation and translocation: A pivotal mechanism of fine particles-exacerbated myocardial hypoxia injury. Environmental Pollution. 10.1016/j.envpol.2022.118937
Liu Bo et al. (2022) CircRbms1 knockdown alleviates hypoxia-induced cardiomyocyte injury via regulating the miR-742-3p/FOXO1 axis. Cellular & Molecular Biology Letters. 10.1186/s11658-022-00330-y
She Kelin et al. (2022) CircRNA 0009043 suppresses non-small-cell lung cancer development via targeting the miR-148a-3p/DNAJB4 axis. Biomarker Research. 10.1186/s40364-022-00407-y
Tingting Cheng et al. (2022) Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer. Free Radical Biology and Medicine. 10.1016/j.freeradbiomed.2022.01.010
Rui Deng et al. (2024) Engineered exosomes loaded with M1–8 peptide for targeted therapy of hepatocellular carcinoma. Applied Materials Today. 10.1016/j.apmt.2024.102071
